The liver X Receptor Agonist AZ876 Protects Against Pathological Cardiac Hypertrophy and Fibrosis Without Lipogenic Side Effects

Abstract

AZ876 activation of LXR protects from adverse cardiac remodelling in pathological pressure overload, independently of blood pressure. LXR may thus represent a putative molecular target for antihypertrophic and antifibrotic therapies in heart failure prevention.